The regulatory costs of developing new medicine are exceedingly high, leading to centralization and capture by Big Pharma. Only these large entities have the funds to satisfy regulators’ demands, and their financial motivations often conflict with their rhetoric of improving lives. Developing a new drug is a complex and expensive process, and unless it promises substantial profits, it’s unlikely to be widely used, regardless of its potential benefits. The post, titled “$200 Billion in Revenue: How an Aging Drug Will Conquer Pharma,” discusses the potential market size for a drug that slows or reverses aging, estimating a peak global market size of $150-$200 billion annually, far surpassing the revenue of current blockbuster drugs. The post also delves into the financial model required for an aging drug, considering factors such as market size, payment sources, drug pricing, and adoption rates over time. The potential long-term healthcare savings and profitability suggest that a drug targeting the aging process could become the largest product in human history.
